Urinary Tract Infection Therapeutics Market is expected to grow at a CAGR of 3.94% through 2031
The expansion of healthcare infrastructure and a supportive regulatory environment are the major drivers of the Global Urinary
Tract Infection Therapeutics Market.
According to TechSci Research report, “Global Urinary
Tract Infection Therapeutics Market Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2021-2031F”, the Global Urinary Tract Infection Therapeutics Market will grow from USD 8.42 Billion in 2025 to USD 10.62 Billion by 2031 at a 3.94% CAGR. This may be due to collaborations and partnerships among leading companies, which enable the integration of individual companies' expertise and strengthen their market positions.
Advances in combination therapies are driving the
demand for urinary tract infection (UTI) therapeutics. They can be more effective in treating UTIs, particularly those caused by resistant bacteria.
And can reduce the risk of
antibiotic resistance. Astellas Pharma is developing fosfomycin-tobramycin therapy. It consists of fosfomycin, an antibiotic effective against a wide range of bacteria, and tobramycin, an antibiotic effective against resistant bacteria. Nitrofurantoin-macrobid therapy is used to treat
uncomplicated UTIs. It consists of nitrofurantoin, an antibiotic effective against the bacteria that cause most UTIs, and macrobid, an antibiotic effective against resistant bacteria.
Browse over XX market data Figures and spread through 110 Pages and an in-depth TOC on " Global Urinary Tract Infection Therapeutics Market”
Numerous infectious
infections can affect patients with severe illnesses and diabetes. The person
has a history of urinary tract infections. Urinary incontinence and irritation are common symptoms among these individuals. More than 15% of the population is significantly affected by UTI. Any age group can be affected by
this virus. Urinary tract infections (UTIs) are becoming more common due to
rising rates of diabetes and kidney stones, which in turn supports the global
UTI epidemic by driving up drug demand.
In September 2021,
Biapenem was launched and made available to patients with intra-abdominal
infections, lower respiratory tract infections, or difficult-to-treat urinary tract infections, according to BDR Pharma, one of India's leading generic pharmaceutical companies. With the release of biapenem under the trade name Biapen, BDR Pharma raises the bar for its extensive line of medicines in the critical care segment. The first company to recognize and develop this product was
BDR Pharma, which also co-sponsored clinical trials with some of the industry's
top competitors in the critical care market. Additionally, BDR Pharma was the
first to obtain DCGI (Drug Controller General of India) approval for this medication. Patients with serious urinary tract infections, intraabdominal
infections, or lower respiratory infections typically receive biapenem
prescriptions. It belongs to a class of essential parenteral carbapenem
antibiotic. Biapen's dosage is considerably lower than that of the current-generation carbapenems.
Patient adherence to
treatment is a challenge for the global urinary tract infection (UTI)
therapeutics market. UTIs are a common infection that affects the urinary
tract, which includes the kidneys, ureters, bladder, and urethra. They are
caused by bacteria that enter the urinary tract through the urethra. The most common symptoms of
a UTI are pain or burning when urinating, frequent urination, and cloudy or
bloody urine. UTIs can be treated with antibiotics, but it is important to
complete the full course of treatment, even if symptoms resolve earlier.
The symptoms of a UTI may
be mild and go away on their own, so patients may not think they need to take
antibiotics. They may forget to
take their antibiotics or be unable to afford them. Bacteria may develop resistance to antibiotics, making it more difficult to treat future infections.
The infection may not be
cured and may worsen.
The global urinary tract infection therapeutics market is segmented by drug, Indication, and
Region.
Based on Drug,
Global Urinary Tract Infection Therapeutics Market is segmented into Penicillin
and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B,
Nitrofurans, and Other Drugs. Penicillin
is an antibiotic effective against a wide range of bacteria, including those that cause urinary tract infections (UTIs). It works by blocking
the formation of the bacteria's cell wall, which is essential for its survival.
It can be used to treat both uncomplicated and complicated UTIs. Uncomplicated
UTIs are those that affect the bladder or urethra, whereas complicated UTIs affect the kidneys or other parts of the urinary tract. Penicillin
is usually given as a single dose or a course of several doses. The duration of treatment will depend on the severity of the infection. Combination
therapy is the use of two or more antibiotics together to treat a UTI. This is
often performed when the bacteria causing the infection are resistant to
single-agent therapy.
By region, North
America dominated the Global Urinary Tract Infection Therapeutics Market.
The region's emphasis on innovation and technological advancements in
healthcare often leads to the introduction of new treatments, including UTI
therapeutics, that can contribute to market dominance. UTIs
are common worldwide, and the North American region is no exception. The high
prevalence of UTIs in the population increases the demand for effective
therapeutics. North America has
well-established regulatory bodies, such as the U.S. Food and Drug
Administration (FDA) and Health Canada, which ensure the safety and efficacy of
pharmaceutical products. This regulatory oversight can foster trust in the
market. While access to healthcare
is a complex issue, North America generally has higher levels of access than some other regions. This can lead to earlier diagnosis and
treatment of UTIs, driving demand for therapeutics.
Europe is the fastest-growing region in the Global Urinary Tract Infection Therapeutics Market. The European region is expected to experience the fastest growth in the global urinary tract infection (UTI) therapeutics market, driven by factors such as the region's increasing UTI prevalence. The rising incidence of diabetes and kidney stones is one of the major risk factors for UTIs. The ageing population is more susceptible to UTIs. The increasing awareness of UTIs
and the importance of early diagnosis and treatment. The availability of new
and improved treatment options. The favourable reimbursement policies for UTI
treatments. According to a study
published in the journal "Urology", the prevalence of UTIs in Europe
is estimated to be around 10% in women and 0.5% in men. The incidence of UTIs
is also higher in women than in men, and it increases with age.
Some of the major companies operating in the Global Urinary Tract
Infection Therapeutics Market include:
- AstraZeneca PLC.
- Bayer AG
- Cipla Inc.
- GlaxoSmithKline PLC
- Shionogi & Co. Ltd
- Novartis AG
- Pfizer Inc.
- Merck & Co. Inc
- Bristol-Myers Squibb Company
- Almirall SA
- Allergan Inc.
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“Certain areas,
particularly in North America, are projected to exert significant demand for urinary
tract infection therapeutics. The growth in the competitive landscape and the presence
of well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Urinary Tract Infection Therapeutics Market in the
forecast period," said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based Global management consulting firm.
Urinary Tract Infection Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs), By Indication (Complicated UTI, Uncomplicated UTI, and Other Indications), and By Region, Competition 2021-2031F, evaluated
the future growth potential of Global Urinary Tract Infection Therapeutics Market
and provides statistics & information on market size, structure, and future
market growth. The report aims to provide innovative market intelligence and support decision-makers in making sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Urinary Tract Infection Therapeutics Market.
Contact
TechSci Research LLC
420 Lexington Avenue
Suite 300, New York
United States- 10170
M: +13322586602
Email: [email protected]
Web: https://www.techsciresearch.com